Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole

@inproceedings{Miller2010ChangesIE,
  title={Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole},
  author={William R. Miller and Alexey Larionov},
  booktitle={Breast Cancer Research},
  year={2010}
}
Clinical resistance is a major factor limiting benefits to endocrine therapy. Causes of resistance may be diverse and the mechanism of resistance in individual breast cancers is usually unknown. The present study illustrates how changes in the expression of proliferation and oestrogen-regulated genes occurring during neoadjuvant treatment with the aromatase inhibitor, letrozole, may define distinctive tumour subgroups and suggest different mechanisms of resistance in clinically endocrine… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 2 Excerpts

PCNA on the crossroad of cancer.

Biochemical Society transactions • 2009
View 1 Excerpt

Aromatase inhibitors--gene discovery.

The Journal of steroid biochemistry and molecular biology • 2007
View 1 Excerpt

Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2006
View 2 Excerpts

Similar Papers

Loading similar papers…